Hill A - Search Results

1

Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.

Hill A, Balkin A. Hill A, et al. AIDS Rev. 2009 Jan-Mar;11(1):30-8. AIDS Rev. 2009. PMID: 19290032 Review.

2

Discordant conclusions from HIV clinical trials--an evaluation of efficacy endpoints.

Hill A, Demasi R. Hill A, et al. Antivir Ther. 2005;10(3):367-74. Antivir Ther. 2005. PMID: 15918328

3

Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

Hill A, Miralles D, Vangeneugden T, Lefebvre E. Hill A, et al. AIDS. 2007 Jul 31;21(12):1651-3. doi: 10.1097/QAD.0b013e3282703593. AIDS. 2007. PMID: 17630565

4

Predicting HIV care costs using CD4 counts from clinical trials.

Hill A, Gebo K. Hill A, et al. Am J Manag Care. 2007 Sep;13(9):524-8. Am J Manag Care. 2007. PMID: 17803366 Free article.

5

Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.

Hill A, Hemmett L, Wilson B. Hill A, et al. HIV Clin Trials. 2007 Sep-Oct;8(5):303-10. doi: 10.1310/hct0805-303. HIV Clin Trials. 2007. PMID: 17956831

6

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.

Hill A, Sawyer W, Gazzard B. Hill A, et al. HIV Clin Trials. 2009 Jan-Feb;10(1):1-12. doi: 10.1310/hct1001-001. HIV Clin Trials. 2009. PMID: 19362991

7

Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.

Gazzard B, Balkin A, Hill A. Gazzard B, et al. Among authors: hill a. AIDS Rev. 2010 Apr-Jun;12(2):67-75. AIDS Rev. 2010. PMID: 20571601 Review.

8

Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.

Winston A, Fätkenheuer G, Arribas J, Hill A, van Delft Y, Moecklinghoff C. Winston A, et al. Among authors: hill a. HIV Clin Trials. 2010 May-Jun;11(3):163-9. doi: 10.1310/hct1103-163. HIV Clin Trials. 2010. PMID: 20736152 Clinical Trial.

9

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.

Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, van Delft Y, Vingerhoets J, Stark T, Marks S. Nelson M, et al. Among authors: hill a. AIDS. 2011 Jan 28;25(3):335-40. doi: 10.1097/QAD.0b013e3283416873. AIDS. 2011. PMID: 21150563

10

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E. Hill AM, et al. Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182345 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,570 results

Search Page

Filters